



**THERMOGENESIS ANNOUNCES ABSTRACTS TO BE PRESENTED
AT UPCOMING STEM CELL THERAPY CONFERENCE**

(RANCHO CORDOVA, CA), April 2, 2009—ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today that its devices will be the subject of several scientific abstracts to be presented at the International Stem Cell Therapy (ISCT) 2009 Annual Meeting in San Diego, May 3-6.

The abstracts will cover the efficacy of the Company's BioArchive[®] System, MarrowXpress[™] (MXP[™]) and Res-Q[™] devices in the processing of stem cells from cord blood and bone marrow. Additional abstracts will address the impact of sterilization practices on stem cell processing, and findings regarding the collection of equine stem cells. The Company will also be demonstrating its products at booth #200.

"We are delighted to have the opportunity to contribute to this leading stem cell industry conference. We believe this forum provides us the opportunity for the industry to be aware of the value of our devices in the collection and storage of stem cells from cord blood and bone marrow, as well as our ability to bring innovation to the market through devices such as the MXP and Res-Q," said Matthew Plavan, Chief Executive Officer of ThermoGenesis.

The abstracts to be presented at the ISCT include:

- Findings from a company study designed to evaluate the efficiency of stem cell recovery from bone marrow following processing with the MXP and cryopreservation with the BioArchive. This study was conducted prior to the commercial launch of the MXP in late 2008. The data demonstrated nearly one hundred percent stem cell recovery and that the MXP can be successfully used to volume reduce and harvest stem cells from human bone marrow in a functionally closed system.
- Results from a company study using the Res-Q, a point-of-care device that enables efficient collection of stem cells from bone marrow aspirate and platelet rich plasma from whole blood in less than 15 minutes. In the study, the device was used to process four bone marrow samples and six peripheral blood units. The device demonstrated the ability to efficiently separate stem cells from both sources in a consistent, uniform volume. The Res-Q is not yet commercially available; the release of this device is expected in June 2009.

- A review by the company of current practices for the sterilization of medical disposables intended for stem cell processing using ethylene oxide (EtO) from a toxicology perspective.
- Three abstracts detailing findings from studies involving the collection of stem cells from equines, including one that demonstrates the effectiveness of the Company's Res-Q for collecting stem cells from equine bone marrow aspirate and platelet rich plasma from whole blood. In addition, studies conducted in conjunction with the University of California, Davis, School of Veterinary Medicine explore the value of equine umbilical cord blood as a source of stem cells and how certain biomaterials may enhance the value of equine stem cells and the implications of these findings for human applications in the future.

“These abstracts are significant as they not only demonstrate the efficacy of our devices, but also with presentations such as our review of sterilization practices, demonstrate ThermoGenesis’ goal of advancing the field of cell therapy,” said John Chapman, PhD, Vice President of Scientific Affairs who directs the Company’s clinical programs. “We look forward to interacting with leading clinicians and solution providers in the stem cell sector at the upcoming ISCT and identifying new opportunities for the use of our cell processing technology,” he added.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

- **The BioArchive® System**, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant.
- **AXP™ AutoXpress Platform (AXP™)** is a proprietary family of automated devices that includes the AXP and the MarrowXpress™ and companion sterile blood processing disposable for harvesting stem cells in a closed system. The AXP device is used for the processing of cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product except for Central and South America, China and Russia/CIS, where ThermoGenesis markets through independent distributors. The MarrowXpress is used for isolating stem cells from bone marrow.
- **The CryoSeal® FS System**, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community. Asahi Medical is the exclusive distributor for the CryoSeal System in Japan and the Company markets through independent distributors in Europe and South America.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2009, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2009. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.

Web site: <http://www.thermogenesis.com>

Contact: Investor Relations

+1-916-858-5107, or

ir@thermogenesis.com